The role of the humoral immune response in the molecular evolution of the envelope C2, V3 and C3 regions in chronically HIV-2 infected patients

Table 1 Virological and immunological characterization of the patients

Patient	Year of diagnosis	Sample	CD4⁺ T cells/μl	RNA copies/ml	Antiretroviral therapy	Antibody reactivity against C2V3C3 (OD/cut-off)
						IgG	IgA
PTHCC1	2001	2003	308	<200	+	14.4	1.41
		2005	319	na		13.3	1.49
PTHCC2	2003	2003	358	<200	+	24.3	1.69
PTHCC4	2000	2003	240	<200	+	9.6	3.26
PTHCC5	1993	2003	480	<200	+	20.1	2.40
		2004	na	<200		22.4	2.14
PTHCC7	2002	2003	144	<200	+	22.9	1.93
		2005	43	<200		22.1	2.42
PTHCC8	2000	2003	141	<200	+	19.4	3.98
		2005	350	na		17.1	3.69
PTHCC12	1995	2003	66	<200	-	28.0	5.79
		2004	84	na		25.5	2.67
PTHCC13	2004	2005	954	<200	-	na	na
PTHCC14	1998	2003	184	<200	+	23.6	3.82
PTHCC17	1998	2003	367	<200	+	22.5	2.74
		2004	270	<200		18.5	2.66
PTHCC19	2003	2003	175	na	+	26.5	1.82
		2004	400	<200		22.3	2.22
		2005	60	na		18.7	2.01
PTHCC20	1998	2003	78	na	+	24.5	1.57
		2004	73	5246		20.0	1.66
		2005	85	<200		19.9	1.37
PTHSM2	2002	2003	275	<200	+	5.9	1.55
		2004	65	<200		6.2	1.57
		2005	122	<200		10.9	1.93
		2006	172	<200		4.7	2.09
PTHSM3	1993	2005	1452	<200	-	7.7	3.47
PTHSM6	2001	2005	471	<200	+	13.9	5.24
PTHSM7	1996	2003	587	na	-	11.4	2.39
PTHSM9	1996	2003	15	<200	+	neg	0.82
		2004	na	484		neg	0.79
PTHSM10	2001	2003	342	5804	+	neg	3.56
		2004	265	4792		neg	3.54
		2005	212	na		neg	3.79

ISSN: 1742-4690